ORIC Pharmaceuticals, Inc. (ORIC) 10-Year Financial Performance & Capital Metrics

ORIC • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Show more

Revenue $0
EBITDA -$142M -29.2%
Net Income -$128M -27.0%
EPS (Diluted) -1.83 +6.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -54.73% -21.3%
ROIC -53.88% -22.7%
Debt/Equity 0.01 -71.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 35.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-12.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.89%

ROCE

10Y Avg-49.52%

5Y Avg-41.68%

3Y Avg-47.24%

Latest-59.11%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.45	53.21	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	11.82B	44.08	25.05	18.49%	29.63%	31.37%	5.36%	0.09
INBXInhibrx Biosciences, Inc.	1.07B	73.28	0.63	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.24B	6.55	-3.10		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.38B	7.94	-3.36	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	987.53M	10.14	-5.54			-33.24%		0.01
ZLABZai Lab Limited	2.07B	18.72	-7.20	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.41B	10.44	-8.77	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	900K	900K	1M	0	0	0	1.03M	1.11M
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-900K	-900K	-1M	0	0	0	-1.03M	-1.11M
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0%	-0.11%	1%	-	-	-	-0.07%
Operating Expenses+	21.64M	22.37M	27.57M	74.19M	78.87M	91.77M	109.75M	141.79M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	2.52M	3.35M	4.72M	13.42M	22.01M	25.09M	25.61M	28.82M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	19.13M	19.03M	22.84M	60.76M	56.86M	61.68M	85.17M	114.07M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	233K	0	0	0	5M	-1.03M	-1.11M
Operating Income+	-22.54M	-22.37M	-28.57M	-74.19M	-78.87M	-91.77M	-110.78M	-142.9M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.01%	-0.28%	-1.6%	-0.06%	-0.16%	-0.21%	-0.29%
EBITDA+	-21.64M	-21.47M	-27.57M	-73.22M	-77.97M	-90.8M	-109.75M	-141.79M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.01%	-0.28%	-1.66%	-0.06%	-0.16%	-0.21%	-0.29%
D&A (Non-Cash Add-back)	900K	900K	1M	970K	897K	966K	1.03M	1.11M
EBIT	-22.54M	-22.37M	-26.88M	-49.34M	-78.87M	-86.77M	-110.78M	-127.85M
Net Interest Income+	0	775K	1.4M	306K	141K	0	10.08M	0
Interest Income	251K	775K	1.4M	306K	141K	2.65M	10.08M	0
Interest Expense	0	0	0	0	0	2.65M	0	0
Other Income/Expense	512K	1.01M	1.69M	483K	156K	2.65M	10.08M	15.05M
Pretax Income+	-22.03M	-21.36M	-26.88M	-73.7M	-78.72M	-89.12M	-100.7M	-127.85M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-22.03M	-21.36M	-26.88M	-73.7M	-78.72M	-89.12M	-100.7M	-127.85M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.03%	-0.26%	-1.74%	-0.07%	-0.13%	-0.13%	-0.27%
Net Income (Continuing)	-22.03M	-21.36M	-26.88M	-73.7M	-78.72M	-89.12M	-100.7M	-127.85M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.74	-1.12	-0.85	-3.36	-2.07	-2.25	-1.96	-1.83
EPS Growth %	-	-0.51%	0.24%	-2.95%	0.38%	-0.09%	0.13%	0.07%
EPS (Basic)	-0.74	-1.12	-0.85	-3.36	-2.07	-2.25	-1.96	-1.83
Diluted Shares Outstanding	29.9M	19.14M	29.9M	21.94M	37.95M	39.66M	51.45M	69.73M
Basic Shares Outstanding	29.9M	19.14M	29.9M	21.94M	37.95M	39.66M	51.45M	69.73M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26.61M	43.72M	90M	296.7M	240.52M	210.46M	212.6M	262.25M
Cash & Short-Term Investments	25.82M	42.64M	89.16M	293.6M	236.98M	206.27M	208.19M	255.96M
Cash Only	25.82M	42.64M	89.16M	78.45M	226.01M	66.84M	23.38M	59.41M
Short-Term Investments	0	0	0	215.15M	10.97M	139.43M	184.8M	196.55M
Accounts Receivable	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	840K	0	0	4.18M	4.41M	6.29M
Total Non-Current Assets+	3.42M	3.01M	4.09M	2.3M	58.12M	39.9M	42.09M	11.89M
Property, Plant & Equipment	2.9M	2.51M	2.24M	1.98M	2.41M	14.25M	12.01M	2.92M
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	43.39M	22.42M	27.34M	0
Other Non-Current Assets	513K	496K	1.85M	319K	12.32M	49K	61K	8.97M
Total Assets+	30.02M	46.73M	94.09M	299M	298.64M	250.36M	254.69M	274.14M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	0.56%	1.01%	2.18%	-0%	-0.16%	0.02%	0.08%
Total Current Liabilities+	2.61M	2.6M	5.35M	9M	15.15M	15.39M	20.46M	24.85M
Accounts Payable	940K	446K	152K	757K	1.89M	1.32M	944K	1.55M
Days Payables Outstanding	381.22	180.88	55.48	-	-	-	333.88	510.41
Short-Term Debt	0	0	0	0	0	2.66M	2.75M	0
Deferred Revenue (Current)	388K	438K	495K	546K	0	0	0	0
Other Current Liabilities	448K	115K	2.82M	0	4.8M	6.09M	10.23M	7.65M
Current Ratio	10.20x	16.84x	16.81x	32.96x	15.87x	13.68x	10.39x	10.56x
Quick Ratio	10.20x	16.84x	16.81x	32.96x	15.87x	13.68x	10.39x	10.56x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.69M	108.56M	765K	219K	10.52M	12.62M	10.14M	6.17M
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	9.44M	7.46M	0
Deferred Tax Liabilities	0	0	0	0	0	3.18M	2.68M	0
Other Non-Current Liabilities	0	107.31M	0	219K	10.52M	0	0	6.17M
Total Liabilities	4.3M	111.16M	6.12M	9.22M	25.67M	28.01M	30.6M	31.02M
Total Debt+	0	0	0	0	1.93M	12.1M	10.21M	3.18M
Net Debt	-25.82M	-42.64M	-89.16M	-78.45M	-224.08M	-54.74M	-13.17M	-56.22M
Debt / Equity	-	-	-	-	0.01x	0.05x	0.05x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-34.69x	-	-
Total Equity+	25.73M	-64.43M	87.97M	289.78M	272.98M	222.35M	224.09M	243.12M
Equity Growth %	-	-3.5%	2.37%	2.29%	-0.06%	-0.19%	0.01%	0.08%
Book Value per Share	0.86	-3.37	2.94	13.21	7.19	5.61	4.36	3.49
Total Shareholders' Equity	25.73M	-64.43M	87.97M	289.78M	272.98M	222.35M	224.09M	243.12M
Common Stock	1K	1K	1K	4K	4K	5K	6K	7K
Retained Earnings	-44.44M	-65.81M	-92.69M	-166.39M	-245.11M	-334.23M	-434.93M	-562.77M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	-2.58M	0	-31K	-103K	-1.29M	258K	379K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.83M	-20.68M	-23.53M	-45.27M	-59.54M	-75.14M	-85.69M	-112.66M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.01%	-0.14%	-0.92%	-0.32%	-0.26%	-0.14%	-0.31%
Net Income	-22.03M	-21.36M	-26.88M	-73.7M	-78.72M	-89.12M	-100.7M	-127.85M
Depreciation & Amortization	900K	903K	1.03M	970K	897K	966K	1.03M	1.11M
Stock-Based Compensation	217	469K	1.09M	5.28M	12.85M	14.46M	15.23M	20.21M
Deferred Taxes	0	0	0	299K	0	0	0	0
Other Non-Cash Items	2M	15K	8K	19.84M	1.35M	-1M	-6.15M	-8.1M
Working Capital Changes	95K	-707K	1.22M	2.04M	4.07M	-445K	4.9M	1.97M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	6K	-410K	986K	4.3M	2.93M	-1.48M	0	1.82M
Cash from Investing+	-292K	-508K	-768K	-215.96M	158.44M	-109.25M	-43.4M	22.14M
Capital Expenditures	-486K	-525K	-768K	-667K	-939K	-2.08M	-849K	-1.19M
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	194K	17K	0	193K	-1.38M	-2.08M	0	0
Cash from Financing+	260K	38.01M	70.82M	250.51M	49.13M	25.23M	85.66M	126.55M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	79K	32K	-20.79M	-866K	225K	658K	1.55M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.32M	-21.21M	-24.3M	-45.94M	-60.48M	-77.22M	-86.54M	-113.85M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	0.01%	-0.15%	-0.89%	-0.32%	-0.28%	-0.12%	-0.32%
FCF per Share	-0.71	-1.11	-0.81	-2.09	-1.59	-1.95	-1.68	-1.63
FCF Conversion (FCF/Net Income)	0.95x	0.97x	0.88x	0.61x	0.76x	0.84x	0.85x	0.88x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-85.63%	-	-228.33%	-39.02%	-27.98%	-35.99%	-45.11%	-54.73%
Return on Invested Capital (ROIC)	-	-	-	-52.95%	-45.46%	-63.58%	-43.9%	-53.88%
Debt / Equity	-	-	-	-	0.01x	0.05x	0.05x	0.01x
Interest Coverage	-	-	-	-	-	-34.69x	-	-
FCF Conversion	0.95x	0.97x	0.88x	0.61x	0.76x	0.84x	0.85x	0.88x

Frequently Asked Questions

Growth & Financials

ORIC Pharmaceuticals, Inc. (ORIC) grew revenue by 0.0% over the past year. Growth has been modest.

ORIC Pharmaceuticals, Inc. (ORIC) reported a net loss of $135.3M for fiscal year 2024.

Dividend & Returns

ORIC Pharmaceuticals, Inc. (ORIC) has a return on equity (ROE) of -54.7%. Negative ROE indicates the company is unprofitable.

ORIC Pharmaceuticals, Inc. (ORIC) had negative free cash flow of $117.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

ORIC Pharmaceuticals, Inc. (ORIC) 10-Year Financial Performance & Capital Metrics

ORIC • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$142M -29.2%
Net Income -$128M -27.0%
EPS (Diluted) -1.83 +6.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -54.73% -21.3%
ROIC -53.88% -22.7%
Debt/Equity 0.01 -71.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 35.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-12.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.89%

ROCE

10Y Avg-49.52%

5Y Avg-41.68%

3Y Avg-47.24%

Latest-59.11%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.45	53.21	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	11.82B	44.08	25.05	18.49%	29.63%	31.37%	5.36%	0.09
INBXInhibrx Biosciences, Inc.	1.07B	73.28	0.63	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.24B	6.55	-3.10		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.38B	7.94	-3.36	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	987.53M	10.14	-5.54			-33.24%		0.01
ZLABZai Lab Limited	2.07B	18.72	-7.20	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.41B	10.44	-8.77	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	900K	900K	1M	0	0	0	1.03M	1.11M
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-900K	-900K	-1M	0	0	0	-1.03M	-1.11M
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0%	-0.11%	1%	-	-	-	-0.07%
Operating Expenses+	21.64M	22.37M	27.57M	74.19M	78.87M	91.77M	109.75M	141.79M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	2.52M	3.35M	4.72M	13.42M	22.01M	25.09M	25.61M	28.82M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	19.13M	19.03M	22.84M	60.76M	56.86M	61.68M	85.17M	114.07M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	233K	0	0	0	5M	-1.03M	-1.11M
Operating Income+	-22.54M	-22.37M	-28.57M	-74.19M	-78.87M	-91.77M	-110.78M	-142.9M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.01%	-0.28%	-1.6%	-0.06%	-0.16%	-0.21%	-0.29%
EBITDA+	-21.64M	-21.47M	-27.57M	-73.22M	-77.97M	-90.8M	-109.75M	-141.79M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.01%	-0.28%	-1.66%	-0.06%	-0.16%	-0.21%	-0.29%
D&A (Non-Cash Add-back)	900K	900K	1M	970K	897K	966K	1.03M	1.11M
EBIT	-22.54M	-22.37M	-26.88M	-49.34M	-78.87M	-86.77M	-110.78M	-127.85M
Net Interest Income+	0	775K	1.4M	306K	141K	0	10.08M	0
Interest Income	251K	775K	1.4M	306K	141K	2.65M	10.08M	0
Interest Expense	0	0	0	0	0	2.65M	0	0
Other Income/Expense	512K	1.01M	1.69M	483K	156K	2.65M	10.08M	15.05M
Pretax Income+	-22.03M	-21.36M	-26.88M	-73.7M	-78.72M	-89.12M	-100.7M	-127.85M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-22.03M	-21.36M	-26.88M	-73.7M	-78.72M	-89.12M	-100.7M	-127.85M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.03%	-0.26%	-1.74%	-0.07%	-0.13%	-0.13%	-0.27%
Net Income (Continuing)	-22.03M	-21.36M	-26.88M	-73.7M	-78.72M	-89.12M	-100.7M	-127.85M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.74	-1.12	-0.85	-3.36	-2.07	-2.25	-1.96	-1.83
EPS Growth %	-	-0.51%	0.24%	-2.95%	0.38%	-0.09%	0.13%	0.07%
EPS (Basic)	-0.74	-1.12	-0.85	-3.36	-2.07	-2.25	-1.96	-1.83
Diluted Shares Outstanding	29.9M	19.14M	29.9M	21.94M	37.95M	39.66M	51.45M	69.73M
Basic Shares Outstanding	29.9M	19.14M	29.9M	21.94M	37.95M	39.66M	51.45M	69.73M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26.61M	43.72M	90M	296.7M	240.52M	210.46M	212.6M	262.25M
Cash & Short-Term Investments	25.82M	42.64M	89.16M	293.6M	236.98M	206.27M	208.19M	255.96M
Cash Only	25.82M	42.64M	89.16M	78.45M	226.01M	66.84M	23.38M	59.41M
Short-Term Investments	0	0	0	215.15M	10.97M	139.43M	184.8M	196.55M
Accounts Receivable	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	840K	0	0	4.18M	4.41M	6.29M
Total Non-Current Assets+	3.42M	3.01M	4.09M	2.3M	58.12M	39.9M	42.09M	11.89M
Property, Plant & Equipment	2.9M	2.51M	2.24M	1.98M	2.41M	14.25M	12.01M	2.92M
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	43.39M	22.42M	27.34M	0
Other Non-Current Assets	513K	496K	1.85M	319K	12.32M	49K	61K	8.97M
Total Assets+	30.02M	46.73M	94.09M	299M	298.64M	250.36M	254.69M	274.14M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	0.56%	1.01%	2.18%	-0%	-0.16%	0.02%	0.08%
Total Current Liabilities+	2.61M	2.6M	5.35M	9M	15.15M	15.39M	20.46M	24.85M
Accounts Payable	940K	446K	152K	757K	1.89M	1.32M	944K	1.55M
Days Payables Outstanding	381.22	180.88	55.48	-	-	-	333.88	510.41
Short-Term Debt	0	0	0	0	0	2.66M	2.75M	0
Deferred Revenue (Current)	388K	438K	495K	546K	0	0	0	0
Other Current Liabilities	448K	115K	2.82M	0	4.8M	6.09M	10.23M	7.65M
Current Ratio	10.20x	16.84x	16.81x	32.96x	15.87x	13.68x	10.39x	10.56x
Quick Ratio	10.20x	16.84x	16.81x	32.96x	15.87x	13.68x	10.39x	10.56x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.69M	108.56M	765K	219K	10.52M	12.62M	10.14M	6.17M
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	9.44M	7.46M	0
Deferred Tax Liabilities	0	0	0	0	0	3.18M	2.68M	0
Other Non-Current Liabilities	0	107.31M	0	219K	10.52M	0	0	6.17M
Total Liabilities	4.3M	111.16M	6.12M	9.22M	25.67M	28.01M	30.6M	31.02M
Total Debt+	0	0	0	0	1.93M	12.1M	10.21M	3.18M
Net Debt	-25.82M	-42.64M	-89.16M	-78.45M	-224.08M	-54.74M	-13.17M	-56.22M
Debt / Equity	-	-	-	-	0.01x	0.05x	0.05x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-34.69x	-	-
Total Equity+	25.73M	-64.43M	87.97M	289.78M	272.98M	222.35M	224.09M	243.12M
Equity Growth %	-	-3.5%	2.37%	2.29%	-0.06%	-0.19%	0.01%	0.08%
Book Value per Share	0.86	-3.37	2.94	13.21	7.19	5.61	4.36	3.49
Total Shareholders' Equity	25.73M	-64.43M	87.97M	289.78M	272.98M	222.35M	224.09M	243.12M
Common Stock	1K	1K	1K	4K	4K	5K	6K	7K
Retained Earnings	-44.44M	-65.81M	-92.69M	-166.39M	-245.11M	-334.23M	-434.93M	-562.77M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	-2.58M	0	-31K	-103K	-1.29M	258K	379K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.83M	-20.68M	-23.53M	-45.27M	-59.54M	-75.14M	-85.69M	-112.66M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.01%	-0.14%	-0.92%	-0.32%	-0.26%	-0.14%	-0.31%
Net Income	-22.03M	-21.36M	-26.88M	-73.7M	-78.72M	-89.12M	-100.7M	-127.85M
Depreciation & Amortization	900K	903K	1.03M	970K	897K	966K	1.03M	1.11M
Stock-Based Compensation	217	469K	1.09M	5.28M	12.85M	14.46M	15.23M	20.21M
Deferred Taxes	0	0	0	299K	0	0	0	0
Other Non-Cash Items	2M	15K	8K	19.84M	1.35M	-1M	-6.15M	-8.1M
Working Capital Changes	95K	-707K	1.22M	2.04M	4.07M	-445K	4.9M	1.97M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	6K	-410K	986K	4.3M	2.93M	-1.48M	0	1.82M
Cash from Investing+	-292K	-508K	-768K	-215.96M	158.44M	-109.25M	-43.4M	22.14M
Capital Expenditures	-486K	-525K	-768K	-667K	-939K	-2.08M	-849K	-1.19M
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	194K	17K	0	193K	-1.38M	-2.08M	0	0
Cash from Financing+	260K	38.01M	70.82M	250.51M	49.13M	25.23M	85.66M	126.55M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	79K	32K	-20.79M	-866K	225K	658K	1.55M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.32M	-21.21M	-24.3M	-45.94M	-60.48M	-77.22M	-86.54M	-113.85M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	0.01%	-0.15%	-0.89%	-0.32%	-0.28%	-0.12%	-0.32%
FCF per Share	-0.71	-1.11	-0.81	-2.09	-1.59	-1.95	-1.68	-1.63
FCF Conversion (FCF/Net Income)	0.95x	0.97x	0.88x	0.61x	0.76x	0.84x	0.85x	0.88x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-85.63%	-	-228.33%	-39.02%	-27.98%	-35.99%	-45.11%	-54.73%
Return on Invested Capital (ROIC)	-	-	-	-52.95%	-45.46%	-63.58%	-43.9%	-53.88%
Debt / Equity	-	-	-	-	0.01x	0.05x	0.05x	0.01x
Interest Coverage	-	-	-	-	-	-34.69x	-	-
FCF Conversion	0.95x	0.97x	0.88x	0.61x	0.76x	0.84x	0.85x	0.88x

Frequently Asked Questions

Growth & Financials

ORIC Pharmaceuticals, Inc. (ORIC) grew revenue by 0.0% over the past year. Growth has been modest.

ORIC Pharmaceuticals, Inc. (ORIC) reported a net loss of $135.3M for fiscal year 2024.

Dividend & Returns

ORIC Pharmaceuticals, Inc. (ORIC) has a return on equity (ROE) of -54.7%. Negative ROE indicates the company is unprofitable.

ORIC Pharmaceuticals, Inc. (ORIC) had negative free cash flow of $117.5M in fiscal year 2024, likely due to heavy capital investments.